U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 2011 - 2020 of 39119 results

Status:
Investigational
Source:
INN:metamelfalan [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Metamelfalan is an antineoplastic agent. Metamelfalan is the meta form of the levo isomer melphalan. Metamelfalan causes crosslinking of DNA, thereby preventing DNA replication and eventually cellular proliferation.
Status:
Investigational
Source:
INN:febuverine
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Febuverine is a spasmolytic and local anesthetic.
Status:
Investigational
Source:
INN:pactimibe [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Daiichi Sankyo developed an inhibitor of acyl-coenzyme A:cholesterol acyltransferases (ACAT1 and ACAT2), pactimibe (also known as CS 505). Pactimibe has been used in trials phase II for reducing the progression of coronary artery disease and in patients with atherosclerosis. However, on October 26, 2005, the company made the decision to discontinue all ongoing clinical studies of pactimibe, because of the secondary endpoints that showed a lower effect of the drug on atherosclerosis than the standard of care alone and no beneficial effect on the frequency of cardiovascular events.
Status:
Investigational
Source:
INN:nafagrel
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.
Status:
Investigational
Source:
INN:flubanilate [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

FLUBANILATE is a CNS stimulant.
Status:
Investigational
Source:
INN:ipsalazide
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

IPSALAZIDE is a sulfasalazine analog designed as a colon-specific delivery system for the treatment of inflammatory bowel disease by releasing 5-aminosalicylic acid in the gastrointestinal tract.
Status:
Investigational
Source:
INN:cefoxazole
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Cefoxazole is a semi-synthetic, first-generation cephalosporin with bactericidal activity against penicillin-resistant strains of S. aureus and used in the treatment of bovine mastitis.
Status:
Investigational
Source:
INN:etiproston
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Etiproston is a synthetic analog of prostaglandin F2α. Etiproston induces luteal regression. Etiproston is used in veterinary.
Status:
Investigational
Source:
INN:esafloxacin
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Esafloxacin (7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid) is an antibacterial agent.
Status:
Investigational
Source:
INN:niometacin
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Niometacin, an indometacin derivative, is a nonsteroidal anti-inflammatory drug.

Showing 2011 - 2020 of 39119 results